Fig 1.
Syntheses of Schiff base ligands and complexes.
Table 1.
Crystal and structure refinement data for complexes 1 and 2.
Fig 2.
Circular dichroism spectra of the H2L1 and complex 1.
Fig 3.
Molecular structures of complex 1, hydrogen atoms are omitted for clarity (Thermal ellipsoids are shown at 50% probability level).
Fig 4.
(a) Right-handed twofold helical chain in 1 linked by intermolecular C–H···π interactions (red dotted line); (b) 3D supramolecular architecture construcated by C–H···π, O–H···O and C–H···O interactions.
Fig 5.
(a) Molecular structures of complex 2, hydrogen atoms are omitted for clarity (Thermal ellipsoids are shown at 50% probability level.); (b) View showing the 3–D structure of complex 2; (c) The independent units A and B appear in pair connecting the infinite chain.
Fig 6.
Solid–state emission spectra of complexes 1 and 2 at room temperature.
Table 2.
IC50 (μM) of all complexes against K-562, HL-60, A549, and HeLa for 48 h treatment.
Fig 7.
Inhibition [%] of complexes 1 and 2 [dose level of 25.0 μM] against human tumor cells.
Fig 8.
Effects of complexes 1 and 2 on the fluorescent spectra of EB–DNA system (λex = 258 nm); CDNA = 30 μM; CEB = 3 μM; from 1 to 6 CVOL = 0, 15, 30, 60, 90, 120 μM, respectively; Inset: plot of I0/I vs r (r = CVOL/CDNA).
Fig 9.
UV-Vis absorption spectra of complexes 1 and 2 (10 μM) in the absence and presence of increasing amounts of DNA (0–10 μM).
Arrow shows the absorbance changes upon increasing DNA concentration.
Fig 10.
CD-spectra of CT-DNA in the absence and presence of complexes 1 and 2, [DNA] = 100 μM, [VOL] = 0 and 40 μM, respectively.